Keymed Advances Gilead Partnership as HK Small-Caps Navigate Uneven Recovery

Divergent financial results and structural shifts defined a cross-section of Hong Kong's mid-to-small cap equities this week, with biotechnology and intelligent manufacturing firms logging significant milestones while traditional retail and advertising operations faced deepening revenue contractions, according to company filings and market data.

Keymed Biosciences (2162.HK)

Keymed Biosciences has drawn institutional focus following major global partnership developments. The company's independently developed CM336 secured FDA Fast Track designation in January 2026. Furthermore, its partner Ouro Medicines completed an acquisition deal with Gilead Sciences in June 2026, a move expected to accelerate the global development of its TCE assets. Domestic brokerages indicate the company is nearing the monetization phase of its overseas business development pipeline.

Bonjour Holdings (0653.HK)

The local cosmetics retailer is navigating a severe liquidity and operational crunch. Financials reported in February 2026 covering the second half of 2025 showed revenue plunging 77.9% to HKD 12.3 million, swinging to a net loss of HKD 68.8 million. According to people familiar with the matter, the executive chairman recently offloaded shares worth approximately HKD 832,000. The company is now targeting logistics tech partnerships to establish cloud warehouse capabilities.

Haina Intelligent Equipment (2185.HK)

The automated machinery maker saw its stock rise over 3% in late July 2026 after striking a strategic partnership with a Shenzhen-based institute to build a joint robotics laboratory. The company is actively expanding its overseas footprint, with its sales network already spanning 20 countries.

China CITIC Bank (3998.HK)

Large-cap financial institutions continue to tap the debt markets. In August 2026, China CITIC Bank announced plans to issue its first tranche of green financial bonds for the year through the Bond Connect program, targeting a scale of RMB 20 billion. The lender recently maintained its AAA rating among top listed companies, underscoring asset stability amid macro fluctuations.

Jingwei Tiandi (2586.HK)

The telecom network service provider has been heavily pressured, with its stock plunging nearly 9.7% to hit a 52-week low in late July 2026. Data indicated anomalous Southbound trading activities during the period, suggesting capital reallocation away from the infrastructure maintenance firm.

Tianhong Cultural & Creative (1920.HK)

Hit by a prolonged slowdown in traditional advertising, the company reported a 37.3% year-over-year revenue drop to RMB 12.7 million for the interim period ending mid-2025. The firm is pivoting toward a comprehensive strategic partner model, though lower margins in its new media segments have yet to offset legacy declines.

GC Construction (1489.HK) & Pak Fah Yeow (0874.HK)

GC Construction logged positive stock momentum over the past 30 days, supported by sustained wet trade project flow in Hong Kong's public and private sectors. Meanwhile, legacy healthcare brand Pak Fah Yeow continues to rely on its 95-year-old product line and overseas property investments in the UK and Singapore to generate defensive cash flows.

Henry Group (3638.HK) & Bay Area Gold (0471.HK)

Diversified conglomerate Henry Group is advancing its dual-engine strategy focused on finance and life sciences. Conversely, mining operator Bay Area Gold highlights the tail-end risks of distressed assets, having been officially delisted by the Hong Kong Stock Exchange after prolonged liquidation proceedings.

This article does not constitute investment advice.